Diabetes Care
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text (PDF)
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Heise, T.
Right arrow Articles by Heinemann, L.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Heise, T.
Right arrow Articles by Heinemann, L.
Social Bookmarking
Add to CiteULike   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

Diabetes Care, Vol 21, Issue 5 800-803, Copyright © 1998 by American Diabetes Association

ARTICLES

Time-action profiles of novel premixed preparations of insulin lispro and NPL insulin

T Heise, C Weyer, A Serwas, S Heinrichs, J Osinga, P Roach, J Woodworth, U Gudat and L Heinemann
Department of Metabolic Diseases and Nutrition, World Health Organization Collaborating Center for Diabetes, Heinrich-Heine-University of Dusseldorf, Germany.

OBJECTIVE: To study the pharmacodynamic properties of three premixed formulations of the rapid-acting insulin analog insulin lispro and its protamine-retarded preparation, neutral protamine lispro (NPL) insulin. RESEARCH DESIGN AND METHODS: In this open, single-center, euglycemic glucose clamp study, 30 healthy volunteers (12 women, 18 men) aged 27 +/- 2 years (mean +/- SD), whose BMI was 23.0 +/- 2.3 kg/m2, received subcutaneous injections of 0.3 U/kg body wt of insulin mixture (high-mixture 75/25, mid-mixture 50/50, or low-mixture 25/75 insulin lispro/NPL insulin), insulin lispro, or NPL insulin on one of the five study days in randomized order. Glucose infusion rates were determined over a period of 24 h after administration. RESULTS: Maximal metabolic activity decreased after subcutaneous injection of the mixtures with lower insulin lispro content; however, the time point of maximal and of early half-maximal metabolic activity was comparable among the three mixtures. Higher proportions of insulin lispro resulted in higher values for area under the curve within the first 360 min after injection and a more rapid decline to late half-maximal activity. Serum insulin concentrations showed a similar pattern. CONCLUSIONS: This study shows that the pharmacodynamic and pharmacokinetic properties of insulin lispro are preserved in stable mixtures with NPL insulin.
Add to CiteULike CiteULike   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
 ANN INTERN MEDHome page
A. D. Mooradian, M. Bernbaum, and S. G. Albert
Narrative Review: A Rational Approach to Starting Insulin Therapy
Ann Intern Med, July 18, 2006; 145(2): 125 - 134.
[Abstract] [Full Text] [PDF]

Home page
 Am J Health Syst PharmHome page
C. Weyer, M. S. Fineman, S. Strobel, L. Shen, J. Data, O. G. Kolterman, and M. F. Sylvestri
Properties of pramlintide and insulin upon mixing
Am. J. Health Syst. Pharm., April 15, 2005; 62(8): 816 - 822.
[Abstract] [Full Text] [PDF]

Home page
 DiabetesHome page
A. D. Cherrington, D. W. Neal, D. S. Edgerton, D. Glass, L. Bowen, C. H. Hobbs, C. Leach, R. Rosskamp, and T. R. Strack
Inhalation of Insulin in Dogs: Assessment of Insulin Levels and Comparison to Subcutaneous Injection
Diabetes, April 1, 2004; 53(4): 877 - 881.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Diabetes Diabetes Care Clinical Diabetes Diabetes Spectrum
Copyright © 1998 by the American Diabetes Association.